2026-06-30T01:54:16Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/184742024-11-28T14:55:39Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16982

00925njm 22002777a 4500 dc Mena-Vázquez, Natalia author Rojas-Gimenez, Marta author Romero-Barco, Carmen María author Manrique-Arija, Sara author Hidalgo Conde, Ana author Arnedo Díez de Los Ríos, Rocío author Cabrera César, Eva author Ortega-Castro, Rafaela author Espildora, Francisco author Aguilar-Hurtado, María Carmen author Añón-Oñate, Isabel author Pérez-Albaladejo, Lorena author Abarca-Costalago, Manuel author Ureña-Garnica, Inmaculada author Velloso-Feijoo, Maria Luisa author Redondo-Rodriguez, Rocio author Fernández-Nebro, Antonio author 2021-09-28 Objectives: To describe the characteristics and progression of interstitial lung disease in patients with associated systemic autoimmune disease (ILD-SAI) and to identify factors associated with progression and mortality. Patients and methods: We performed a multicenter, retrospective, observational study of patients with ILD-SAI followed between 2015 and 2020. We collected clinical data and performed pulmonary function testing and high-resolution computed tomography at diagnosis and at the final visit. The main outcome measure at the end of follow-up was forced vital capacity (FVC) >10% or diffusing capacity of the lungs for carbon monoxide >15% and radiological progression or death. Cox regression analysis was performed to identify factors associated with worsening of ILD. Results: We included 204 patients with ILD-SAI: 123 (60.3%) had rheumatoid arthritis (RA), 58 had (28.4%) systemic sclerosis, and 23 (11.3%) had inflammatory myopathy. After a median (IQR) period of 56 (29.8–93.3) months, lung disease had stabilized in 98 patients (48%), improved in 33 (16.1%), and worsened in 44 (21.5%). A total of 29 patients (14.2%) died. Progression and hospitalization were more frequent in patients with RA (p = 0.010). The multivariate analysis showed the independent predictors for worsening of ILD-SAI to be RA (HR, 1.9 [95% CI, 1.3–2.7]), usual interstitial pneumonia pattern (HR, 1.7 [95% CI, 1.0–2.9]), FVC (%) (HR, 2.3 [95% CI, 1.4–3.9]), and smoking (HR, 2.7 [95%CI, 1.6–4.7]). Conclusion: Disease stabilizes or improves after a median of 5 years in more than half of patients with ILD-SAI, although more than one-third die. Data on subgroups and risk factors could help us to predict poorer outcomes. 10.3390/diagnostics11101794 2075-4418 Diagnostics http://hdl.handle.net/10668/3975 34679492 http://hdl.handle.net/20.500.12105/18474 Rheumatoid arthritis Systemic autoimmune disease Interstitial lung disease Prognosis Smoking Artritis reumatoide Enfermedades autoinmunes Enfermedades pulmonares intersticiales Pronóstico Fumar Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study